According to our (Global Info Research) latest study, the global Subcutaneous Drug Delivery Equipment market size was valued at US$ 37042 million in 2025 and is forecast to a readjusted size of US$ 60014 million by 2032 with a CAGR of 8.0% during review period.
Subcutaneous Drug Delivery Equipment refers to a class of drug delivery devices or systems that administer drugs into the subcutaneous tissue, with the core value of bypassing the skin's stratum corneum barrier to achieve efficient drug absorption. From an industry perspective, this field encompasses three major technological forms. The first is traditional needle-based devices such as auto-injectors and prefilled syringes. The second is on-body injectors, which are wearable devices that adhere to the skin and can be programmed to automatically complete subcutaneous delivery of large-volume or high-viscosity drugs. The third is implantable devices such as subcutaneous implants and implantable infusion ports. The subcutaneous tissue lies beneath the dermis and consists of loose connective tissue and adipose tissue, rich in capillaries and lymphatic vessels, allowing drugs to rapidly enter systemic circulation after injection while exhibiting low local proteolytic enzyme activity, making it particularly suitable for the delivery of large-molecule drugs. In recent years, with the explosive growth of biologics, subcutaneous drug delivery has transitioned from a complementary approach to intravenous infusion into the core infrastructure for biologic commercialization. This shift not only compresses the single administration time from tens of minutes for intravenous infusion to minutes, but also drives the migration of treatment settings from hospitals to homes, enabling patients or their caregivers to perform administration, thereby reshaping the competitive landscape of the global pharmaceutical industry.
Market Development Opportunities and Key Drivers
The mature application of recombinant human hyaluronidase has enabled single subcutaneous injection volume to surpass the traditional 1.5 mL limit, removing barriers for subcutaneous administration of biologics such as monoclonal antibodies and peptides. The rising global prevalence of chronic diseases is driving rigid demand for home-use drug delivery devices. In 2024, the U.S. Food and Drug Administration consecutively approved multiple subcutaneous tumor immunotherapy products, while China's National Medical Products Administration included subcutaneous drug delivery formulations in the expansion categories for generic drug consistency evaluation. Large pharmaceutical companies are treating subcutaneous drug delivery platforms as strategic assets to extend core product lifecycles through acquisitions and collaborations.
Market Challenges and Risks
As drug-device combination products, subcutaneous drug delivery equipment must satisfy dual regulatory review requirements for both pharmaceuticals and devices, and divergent interpretations of the primary mode of action across jurisdictions often lead to extended review cycles. The European Medical Device Regulation has elevated auto-injectors to Class III status while notified body certification capacity remains constrained. Wearable injectors carry high costs, making widespread adoption difficult in self-pay dominant markets, and U.S. payers commonly require prior authorization for biologics with high annual costs. Critical components remain concentrated among a limited number of suppliers, making supply chain geopolitical risks a concern.
Downstream Demand Trends
Large pharmaceutical companies are treating subcutaneous drug delivery platforms as strategic assets to counter biosimilar competition through acquisitions and licensing. In 2025, Enable Injections' enFuse system received regulatory approvals from both Brazil and the United Kingdom, signaling that wearable large-volume subcutaneous injection technology is gaining global regulatory acceptance. Chronic disease patients favor wearable injectors that can be worn for hours to automatically complete drug delivery, while oncology patients value the reduction of treatment time from half a day to minutes. The United Kingdom government has initiated a multi-billion pound program to promote hybrid closed-loop insulin systems, reflecting public payers' confidence in home-based subcutaneous drug delivery models.
Regional Trends
North America continues to dominate innovation and early commercialization, leveraging its dense biopharmaceutical clusters and mature drug-device combination review experience, with the U.S. Food and Drug Administration approving multiple subcutaneous tumor immunotherapy products in 2024. Europe emphasizes real-world evidence and health technology assessment, with Germany's Federal Joint Committee imposing stricter requirements for additional benefit assessment of novel drug-device combination products, positioning the region as a critical proving ground for clinical and economic value. China and the broader Asia-Pacific region are transitioning from generic following to integrated innovation, with large chronic disease patient populations and rapidly iterating manufacturing capabilities providing unique engineering advantages for local companies.
This report is a detailed and comprehensive analysis for global Subcutaneous Drug Delivery Equipment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Subcutaneous Drug Delivery Equipment market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (USD/Unit), 2021-2032
Global Subcutaneous Drug Delivery Equipment market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (USD/Unit), 2021-2032
Global Subcutaneous Drug Delivery Equipment market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (USD/Unit), 2021-2032
Global Subcutaneous Drug Delivery Equipment market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Subcutaneous Drug Delivery Equipment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Subcutaneous Drug Delivery Equipment market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Becton Dickinson, Ypsomed, SHL Medical, West Pharmaceutical Services, Gerresheimer, Owen Mumford, Novo Nordisk, Nemera, Tandem Diabetes Care, Enable Injections, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Subcutaneous Drug Delivery Equipment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Syringe
Injection Pen
Implantable Device
Market segment by Delivery Mechanism
Manual Injection Device
Spring Driven Device
Motor Driven Device
Gas-Powered Device
Market segment by Drug Type
Small Molecule Device
Peptide and Protein Device
Nucleic Acid Device
Market segment by Reusability
Disposable Device
Reusable Device
Market segment by Application
Disease Treatment
Vaccination
Aesthetics and Cosmetics
Major players covered
Becton Dickinson
Ypsomed
SHL Medical
West Pharmaceutical Services
Gerresheimer
Owen Mumford
Novo Nordisk
Nemera
Tandem Diabetes Care
Enable Injections
Stevanato Group
MicroPort
Weigao Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Subcutaneous Drug Delivery Equipment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Subcutaneous Drug Delivery Equipment, with price, sales quantity, revenue, and global market share of Subcutaneous Drug Delivery Equipment from 2021 to 2026.
Chapter 3, the Subcutaneous Drug Delivery Equipment competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Subcutaneous Drug Delivery Equipment breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Subcutaneous Drug Delivery Equipment market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Subcutaneous Drug Delivery Equipment.
Chapter 14 and 15, to describe Subcutaneous Drug Delivery Equipment sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Subcutaneous Drug Delivery Equipment. Industry analysis & Market Report on Subcutaneous Drug Delivery Equipment is a syndicated market report, published as Global Subcutaneous Drug Delivery Equipment Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Subcutaneous Drug Delivery Equipment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.